Edition:
India

People: Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

18.56USD
2:29am IST
Change (% chg)

$0.19 (+1.03%)
Prev Close
$18.37
Open
$18.55
Day's High
$19.48
Day's Low
$18.28
Volume
12,879
Avg. Vol
19,151
52-wk High
$36.28
52-wk Low
$14.46

Fust, Matthew 

Mr. Matthew K. Fust is Independent Director of the Company. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 through its acquisition by Amgen Inc. in October 2013. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a genetics company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. Mr. Fust serves on the board of directors of the following publicly traded companies: Dermira, Inc., a biopharmaceutical company, Atara Biotherapeutics, Inc., a biopharmaceutical company, MacroGenics, Inc., a biopharmaceutical company, and Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company. Mr. Fust served on the board of directors of Sunesis Pharmaceuticals, Inc. from May 2005 until May 2017. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business. Mr. Fust’s experience as a chief financial officer in the life sciences industry, his leadership and management experience, and his service as a director of other biopharmaceutical companies, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 27,391
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 55,180
Fiscal Year Total, USD 82,571

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --